Product Information
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE is a generic product labeled by Ingenus Pharmaceuticals LLC, priced at $2.4028 per EA under NDC 50742028313. Its NADAC has been published 142 times since Jan 17, 2024.
FDA first approved this application on Jul 3, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE
Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochlorideStrength
140; 125; 125 mg/1; mg/1; mg/1
Manufacturer
Ingenus Pharmaceuticals LLCNDC
50742028313
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA217511FDA Approved
7/3/2023
TE Code
AB
On Market Since
7/4/2023
Pharmacological Classes
Price Statistics
The NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has been published 142 times since Jan 17, 2024, and over the history we have for it it has declined 53.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.4028 per EA |
|---|---|
| All-time high | $5.1282 (Feb 14, 2024) |
| All-time low | $2.3760 (Aug 19, 2026) |
| 52-week high | $3.6473 |
| 52-week low | $2.3760 |
| Median price | $3.5984 |
| Average price | $3.5313 |
| Largest weekly change | -22.6% (Jul 17, 2024) |
| Weeks tracked | 142 |
| Tracking since | Jan 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ingenus Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bismuth class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, manufactured by Ingenus Pharmaceuticals LLC, is $2.4028 per EA (NDC 50742028313), effective Sep 30, 2026.
How has the price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has declined 53.1%. It has been tracked across 142 weekly CMS publications since Jan 17, 2024.
What are the highest and lowest recorded NADAC prices for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
Since Jan 17, 2024, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has ranged from a low of $2.3760 (Aug 19, 2026) to a high of $5.1282 (Feb 14, 2024), with a median of $3.5984 per EA.
Are there cheaper alternatives to BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE (NDC 50742028313) is labeled by Ingenus Pharmaceuticals LLC, and CMS classifies it as a generic product.